SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending strongly as the stock breaks into new territory, fueled by news related to China's potential export restrictions on rare earth minerals. The community is bullish, anticipating further gains and a potential short squeeze, while also eyeing long-term prospects tied to deep-sea mining and critical mineral demand. Traders are closely watching for news catalysts and technical formations that could drive the stock higher.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver nears a multi-decade high, driven by industrial demand and potential Fed rate cuts, sparking community discussion about a possible breakout. Community members are actively discussing if it will break through the $50 resistance, and some believe a short squeeze is imminent. Some analysts say the stock has more room to run, despite global economic uncertainty.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company ($ABAT) is trending as traders discuss the potential impact of lithium export controls from China, with some seeing it as a boon for ABAT's energy independence mission. Community members are also anticipating the release of the PFS (Pre-Feasibility Study) and speculating on potential partnerships or government stakes. Bullish sentiment is fueled by the company's position in the battery recycling and lithium production sector.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending as investors await potential news from the upcoming Gen AI Summit and Q3 earnings report, with community members speculating on possible acquisitions or major contracts. Bullish sentiment is fueled by the recent surge in stock price, institutional buying, and lack of insider selling, while some traders express caution and highlight technical indicators. Discussions also mention potential price targets, fair valuations, and the company's positioning in the AI data market relative to competitors.

Global Health Solutions Inc is an American company that works with partners to eliminate diseases that have plagued humanity for centuries and protect the health of populations by helping countries build strong health systems. The private company is located in the US. The company brings together key stakeholders around the world with a common goal to stop diseases and strengthen health systems through powerful partnerships. The company consists of programs and focus areas that cover a range of health issues including neglected tropical diseases, infectious diseases, vaccines, field epidemiology, public health informatics, health workforce development, and health ethics. The company's end goal is to eliminate diseases and protect the health of populations.

Turn Therapeutics Inc.

Turn Therapeutics Inc

Turn Therapeutics ($TTRX) is trending after its recent IPO, with the community discussing its potential for significant gains. Some traders are cautious, pointing to valuation concerns and possible formations on the minute chart, while others see it as the next stock poised for a substantial surge, drawing comparisons to other recent high-flying IPOs.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to increasing community discussion around its potential transition into AI infrastructure, drawing comparisons to early NVIDIA. Bullish sentiment is fueled by growing optimism for the Cayuga site approval and anticipation of a short squeeze, given the high short interest and Google's backing. Some investors highlight TeraWulf's advantageous position in the energy sector, which could be critical for AI data centers, while others point to potential delays and dilution concerns.

Aventus Network

Aventus Network ($AVT) is trending, with community members discussing its potential and recent partnerships. Some are pointing to its low market cap and real-world applications in cargo management as reasons for optimism. Mentions of its integration with Polkadot and listing on Coinbase are also circulating.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as spot silver prices reach new highs, sparking excitement among investors. The community is actively discussing loading up on silver miners and anticipating further gains, drawing comparisons to gold's previous rallies. Some are pointing out the potential for silver miners to go mainstream, while others are debating realistic price targets.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics ($SERV) is trending due to a newly announced partnership with DoorDash to expand autonomous sidewalk robot deliveries nationwide, with community members expressing excitement and discussing the potential impact. The multi-year deal builds on Serve's existing operations with Uber Eats, maximizing robot utilization, and investors are betting on the future of last-mile logistics within the robotics sector. Community members are closely watching key technical levels and anticipating further upside.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors speculate about a potential acquisition following increased M&A activity in the metabolic disease space, highlighted by the recent AKRO and MTSR deals. Community discussions revolve around potential buyout offers and the possibility of a short squeeze, with many believing VKTX is undervalued given its pipeline and recent data. The focus is now shifting towards MASH opportunities, adding another layer of potential value for the company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clinical stage biotech company Vaccinex’s ($VCNX) stock was up nearly 16% (1:54 pm ET) on Thursday afternoon after the company said it will provide an update on safety and efficacy data from its Alzheimer’s drug study, lifting retail sentiment.Rochester, N.Y.-based Vaccinex said it will present ‘promising’ new efficacy and safety data for a randomized, double-blind, phase 1b/2 SIGNAL-AD study for the treatment of Alzheimer’s disease. Its lead product candidate is related to studying pepinemab antibody, aimed at treating early stages of Alzheimer’s disease. The company’s last update on positive clinical findings from its SIGNAL-AD Phase 1b/2 trial were made in August.VCNX stock is up 19.53% this week.Retail sentiment on the stock turned ‘bullish’ (72/100) from ‘neutral’ (50/100) a week ago with message volumes climbing into the ‘high’ zone compared to ‘normal’ last week.<figure class="image"><img style="aspect-ratio:1308/370;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_24_at_10_54_58_PM_16e50ec661.png" alt="Screenshot 2024-10-24 at 10.54.58 PM.png" width="1308" height="370"><figcaption>VCNX sentiment meter as of 1:25 pm ET</figcaption></figure>Many Stocktwits users were optimistic about its prospects even though the company has faced headwinds this year due to a challenging macro environment for biotech companies.<stembedurl>https://stocktwits.com/Pbonk/message/590003737</stembedurl><stembedurl>https://stocktwits.com/Krystian_v/message/589974260</stembedurl>As on December 31, 2023, the company’s cash and cash equivalents and marketable securities stood at $1.5 million, down from $6.4 million as of Dec. 31, 2022. In Oct. 2023, the company raised $9.6 million from the sale of common stock and warrants.VCNX stock is down 71% year-to-date.For updates and corrections, email newsroom@stocktwits.com&nbsp;

Vaccinex Stock Spikes On 'Promising' Data On Alzheimer’s Drug Study: Retail Sentiment Brightens

The Rochester, N.Y.-based firm said it will present ‘promising’ new efficacy and safety data for the treatment of Alzheimer’s disease later this month.

Vaccinex Stock Spikes On Promising Data On Alzheimer’s Drug Study: Retail Sentiment Brightens

Equity

What's Going On With Vaccinex Stock Wednesday?

Vaccinex shares are trading lower on Wednesday after the company announced $6.2 million in proceeds from the exercise of warrants as well as the issuance of new warrants for common stock.
read more...

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER...

Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Decrease in Short Interest

Vaccinex, Inc. (NASDAQ:VCNX - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 8,800 shares, a decline of 40.5% from the...

Vaccinex to raise $1.5M through in a direct offering

Vaccinex to raise $1.5M through in a direct offering...

Vaccinex prices 193,000 shares at $7.77 in registered direct offering

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ( Vaccinex or the Company ), a clinical-stage biotechnology company pioneering a differentiated approach to...

12 acciones de salud en movimiento durante la preapertura del 26/02/2024

Acciones al alza
ZyVersa Therapeutics (NASDAQ:ZVSA) avanzaron un 47,31% para establecerse en los 1,18 d lares durante la sesi n del pre-market del lunes.
Vaccinex (NASDAQ:VCNX) crecieron un 43,64...

Vaccinex Announces Multiple New Agreements for Access to ActivMAb  Antigen Virus Technology

Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb Drug Discovery Platform ActivMab platform enables the discovery and development of high value antibodies against...

Vaccinex trading halted, news pending

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Vaccinex Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$0.5101
Prev Close	$0.64
Open	$0.5254
Dividend Yield	0.00%
50-Day Moving Average	$0.6333
Beta	1.80
Avg. Volume	1,415.67
PE Ratio	-0.05

52-Week High	$4.81
52-Week Low	$0.2521
Market Capitalization	$1.37M
EPS (Annual)	-$8.88
Price to Book	-0.33
Revenue Per Employee	$22,259.26
Enterprise Value/EBITDA	N/A

VCNX
Vaccinex Inc

Feed

News

Sentiment

Fundamentals

Info

Latest VCNX News

VCNX Vaccinex Inc